Ubiquitination and the ubiquitin - Proteasome system in the pathogenesis and treatment of squamous head and neck carcinoma

Anticancer Research

Volumn 33, Issue 9, 2013, Pages 3527-3542

  Voutsadakis, Ioannis A ^a  

^a Department of Diagnostic Imaging   (Canada)

Author keywords

Carcinogenesis; Head and neck carcinoma; Review; Squamous; Ubiquitin ligases; Ubiquitin proteasome system; Ubiquitination

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CASPASE 9; CISPLATIN; CYCLIN A; CYCLIN B; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; DOCETAXEL; F BOX PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTAGLANDIN SYNTHASE; PROTEASOME; PROTEIN E6; PROTEIN E7; PROTEIN MDM2; PROTEIN P53; TIGHT JUNCTION PROTEIN; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UVOMORULIN;

ACETYLATION; ACTIN FILAMENT; AMINO TERMINAL SEQUENCE; ANGIOGENESIS; APOPTOSIS; AUTOPHAGY; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL DEATH; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONFORMATIONAL TRANSITION; DNA DAMAGE; DNA REPAIR; DNA TRANSCRIPTION; DOWN REGULATION; ENDOCYTOSIS; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE PRODUCT; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; RING FINGER MOTIF; SIGNAL TRANSDUCTION; TIGHT JUNCTION; UBIQUITINATION; VIRUS CARCINOGENESIS;

CARCINOGENESIS; HEAD AND NECK CARCINOMA; REVIEW; SQUAMOUS; UBIQUITIN LIGASES; UBIQUITIN-PROTEASOME SYSTEM; UBIQUITINATION;

HEAD AND NECK NEOPLASMS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN; UBIQUITINATION;

EID: 84884993231     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (146)

1. Haddad RI and Shin DM: Recent advances in head and neck cancer. New Engl J Med 359: 1143-1154, 2008.
2. Vidal L and Gillison ML: Human papillomavirus in HNSCC: Recognition of a distinct disease type. Hematol Oncol Clin North Am 22: 1125-1142, 2008.
3. Leemans CR, Braakhuis BJM and Brakenhoff RH: The molecular biology of head and neck cancer. Nature Rev Cancer 11: 9-22, 2011.
4. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP and Gillison ML: Human papillomavirus and survival of patients with oropharyngeal cancer. New Engl J Med 363: 24-35, 2010.
5. Molinolo AA, Marsh C, El Dinali M, Gangane N, Jennison K, Hewitt S, Patel V, Seiwert TY and Gutkind JS: mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas. Clin Cancer Res 18: 2558-2568, 2012.
6. Rotin D and Kumar S: Physiological functions of the HECT family of ubiquitin ligases. Nature Rev Mol Cell Biol 10: 398-409, 2009.
7. Vousden KH and Prives C: Blinded by the SteLight: The growing complexity of p53. Cell 137: 413-431, 2009.
8. Wiest T, Schwarz E, Enders C, Flechtenmacher C and Bosch FX: Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 21: 1510-1517, 2002.
9. Stevens C and La Thangue NB: E2F and cell cycle control; a double-edged sword. Arch Biochem Biophys 412: 157-169, 2003.
10. Nakagawa S and Huibregtse JM: Human Scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol Cell Biol 20: 8244-8253, 2000.
11. Banks L, Pim D and Thomas M: Human tumour viruses and the deregulation of cell polarity in cancer. Nature Rev Cancer 12: 877-886, 2012.
12. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, Westra W, Sidransky D and Koch WM: Tp53 mutations and survival in squamous-cell carcinoma of the head and neck. New Engl J Med 357: 2552-2561, 2007.
13. Solomon H, Madar S and Rotter V: Mutant p53 gain of function is interwoven into the hallmarks of cancer. J Pathol 225: 475-478, 2011.
14. Acin S, Li Z, Mejia O, Roop DR, El-Naggar AK and Caulin C: Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic KRAS. J Pathol 225: 479-489, 2011.
15. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J and Sidransky D: High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56: 3630-3633, 1996.
16. Gibcus JH, Menkema L, Mastik MF, Hermsen MA, de Bock GH, van Velthuysen ML, Takes RP, Kok K, Alvarez Marcos CA, van der Laan BF, van den Brekel MW, Langendijk JA, Kluin PM, van der Wal JE and Schuuring E: Amplicon mapping and expression profiling identify the Fas-associated death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal cancer. Clin Cancer Res 13: 6257-6266, 2007.
17. Hama T, Yuza Y, Saito Y, O-uchi J, Kondo S, Okabe M, Yamada H, Kato T, Moriyama H, Kurihara S and Urashima M: Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 14: 900-908, 2009.
18. Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, Morgan S, Ferris RL, Grandis JR and Siegfried JM: HGF and c-MET participate in paracrine tumorigenic pathways in head and neck squamous cell carcinoma. Clin Cancer Res 15: 3740-3750, 2009.
19. Qiu W, Schönleben F, Li X, Ho DJ, Close LG, Manolidis S, Bennett BP and Su GH: PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 12: 1441-1446, 2006.
20. Okami K, Wu L, Riggins G, Cairns P, Goggins M, Evron E, Halachmi N, Ahrendt SA, Reed AL, Hilgers W, Kern SE, Koch WM, Sidransky D and Jen J: Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res 58: 509-511, 1998.
21. Massagué J: TGFβ signalling in context. Nature Rev Mol Cell Biol 13: 616-630, 2012.
22. Zhang YE: Non-SMAD pathways in TGF-beta signalling. Cell Res 19: 128-139, 2009.
23. Voutsadakis IA: The ubiquitin-proteasome system in colorectal cancer. Biophys Biochim Acta 1782: 800-808, 2008.
24. Behrends C and Harper JW: Constructing and decoding unconventional ubiquitin chains. Nature Struct Mol Biol 18: 520-528, 2011.
25. Voutsadakis IA: Ubiquitin, ubiquitination and the ubiquitinproteasome system in cancer. Atlas Genet Cytogen Oncol Haematol. URL: http// AtlasGeneticsOncology.org/Deep/ UbiquitinCancerID20083.httml, 2010.
26. Hochstrasser M: Origin and function of ubiquitin-like proteins. Nature 458: 422-429, 2009.
27. Groettrup M, Pelzer C, Schmidtke G and Hofmann K: Activating the ubiquitin family: UBA6 challenges the field. Trends Biochem Sci 33: 230-237, 2008.
28. Schulman BA and Harper JW: Ubiquitin-like protein activation by E1 enzymes: The apex for downstream signaling pathways. Nature Rev Mol Cell Biol 10: 319-331, 2009.
29. Ye Y and Rape M: Building ubiquitin chains: E2 enzymes at work. Nature Rev Mol Cell Biol 10: 755-764, 2009.
30. Wenzel DM, Stoll KE and Klevit RE: E2s: Structurally economical and functionally replete. Biochem J 433: 31-42, 2011.
31. Passmore LA and Barford D: Getting into position: The catalytic mechanisms of protein ubiquitylation. Biochem J 379: 513-525, 2004.
32. Wenzel DM and Klevit RE: Following Ariadne's thread: A new perspective on RBR ubiquitin ligases. BMC Biol 10: 24, 2012.
33. Li W and Ye Y: Polyubiquitin chains: Functions, structures, and mechanisms. Cell Mol Life Sci 65: 2397-2406, 2008.
34. Kulathu Y and Komander D: Atypical ubiquitylation-the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nature Rev Mol Cell Biol 13: 508-523, 2012.
35. Haglund K and Dikic I: The role of ubiquitylation in receptor endocytosis and endosomal sorting. J Cell Sci 125: 265-275, 2012.
36. Clague MJ, Coulson JM and Urbé S: Cellular functions of the DUBs. J Cell Sci 125: 277-286, 2012.
37. Komander D, Clague MJ and Urbé S: Breaking the chains: Structure and function of the deubiquitinases. Nature Rev Mol Cell Biol 10: 550-563, 2009.
38. Reits EA, Benham AM, Plougaste B, Neefles J and Trowsdale J: Dynamics of proteasome distribution in living cells. EMBO J 16: 6087-6094, 1997.
39. Tian G and Finley D: Destruction deconstructed. Nature 482: 170-171, 2012.
40. Wolf DH and Hilt W: The proteasome: A proteolytic nanomachine of cell regulation and waste disposal. Biochim Biophys Acta 1695: 19-31, 2004.
41. Belyi VA, Ak P, Markert E, Wang H, Hu W, Puzio-Kuter A and Levine AJ: The origins and evolution of the p53 family of genes. Cold Spring Harb Perspect Biol 2: a001198, 2010.
42. Meulmeester E, Maurice MM, Boutell C, Teunisse AF, Ovaa H, Abraham TE, Dirks RW and Jochemsen AG: Loss of HAUSPmediated deubiquitination contributes to DNA damage-induced destabilization of HDMX and HDM2. Mol Cell 18: 565-576, 2005.
43. Horn HF and Vousden KH: Coping with stress: Multiple ways to activate p53. Oncogene 26: 1306-1316, 2007.
44. Dai C and Gu W: p53 post-translational modification: Deregulated in tumorigenesis. Trends Mol Med 16: 528-536, 2010.
45. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, Yu WH, Rehman SK, Hsu JL, Lee HH, Liu M, Chen CT, Yu D and Hung MC: p53 regulates epithelial- mesenchymal transition and stem cell properties through modulating miRNAs. Nature Cell Biol 13: 317-323, 2011.
46. Kim T, Veronese A, Pichiorri F, Lee TJ, Jeon YJ, Volinia S, Pineau P, Marchio A, Palatini J, Suh SS, Alder H, Liu CG, Dejean A and Groce CM: p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 208: 875-883, 2011.
47. Pinho AV, Rooman I and Real FX: p53-dependent regulation of growth, epithelial-mesenchymal transition and stemness in normal pancreatic epithelial cells. Cell Cycle 10: 1312-1321, 2011.
48. Wang SP, Wang WL, Chang YL, Wu CT, Chao YC, Kao SH, Yuan A, Lin CW, Yang SC, Chan WK, Li KC, Hong TM and Yang PC: p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nature Cell Biol 11: 694-704, 2009.
49. Munro S, Carr SM and La Thangue NB: Diversity within the pRb pathway: Is there a code of conduct? Oncogene 31: 4343-4352, 2012.
50. Lewis JS Jr: p16 immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol 6(Suppl 1): S75-S82, 2012.
51. Smeets SJ, Braakhuis BJ, Abbas S, Snijders PJ, Ylstra B, van de Wiel MA, Meijer GA, Leemans CR and Brakenhoff RH: Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogeneexpressing human papillomavirus. Oncogene 25: 2558-2564, 2006.
52. Gil J and Peters G: Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Cell Biol 7: 667-677, 2006.
53. Uchida C, Miwa S, Kitagawa K, Hattori T, Isobe T, Otani S, Oda T, Sugimura H, Kamijo T, Ookawa K, Yasuda H and Kitagawa M: Enhanced MDM2 activity inhibits pRB function via ubiquitin-dependent degradation. EMBO J 24: 160-169, 2005.
54. Miyake S, Sellers WR, Safran M, Li X, Zhao W, Grossman SR, Gan J, DeCaprio JA, Adams PD and Kaelin WG Jr.: Cells degrade a novel inhibitor of differentiation with E1A-like properties upon exiting the cell cycle. Mol Cell Biol 20: 8889-8902, 2000.
55. Marti A, Wirbelauer C, Scheffner M and Krek W: Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nature Cell Biol 1: 14-19, 1999.
56. Kanie T, Onoyama I, Matsumoto A, Yamada M, Nakatsumi H, Tateishi Y, Yamamura S, Tsunematsu R, Matsumoto M and Nakayama KI: Genetic reevaluation of the role of F-box proteins in cyclin D1 degradation. Mol Cell Biol 32: 590-605,2012.
57. Macleod KF, Hu W and Jacks T: Loss of Rb activates both p53-dependent and independent cell death pathways in the developing mouse nervous system. EMBO J 15: 6178-6188, 1996.
58. Jiang Z, Liang P, Leng R, Guo Z, Liu Y, Liu X, Bubnic S, Keating A, Murray D, Goss P and Zacksenhaus E: E2F1 and p53 are dispensable, whereas p21Waf1/Cip1 cooperates with Rb to restrict endoreduplication and apoptosis during skeletal myogenesis. Dev Biol 227: 8-41, 2000.
59. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, Solari A, Bobisse S, Rondina MB, Guzzardo V, Parenti AR, Rosato A, Bicciato S, Balmain A and Piccolo S: A Mutantp53/ SMAD complex opposes p63 to empower TGFβ-induced metastasis. Cell 137: 87-98, 2009.
60. Gal A, Sjöblom T, Fedorova L, Imreh S, Beug H and Moustakas A: Sustained TGFβ exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis. Oncogene 27: 1218-1230, 2008.
61. Yang Y, Pan X, Lei W, Wang J and Song J: Transforming growth factor-β1 induces epithelial-to-mesenchymal transition and apoptosis via a cell cycle-dependent mechanism. Oncogene 25: 7235-7244, 2006.
62. Song J: EMT or apoptosis: A decision for TGF-β. Cell Res 17: 289-290, 2007.
63. Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T and Springer TA: Latent TGF-β structure and activation. Nature 474: 343-349, 2011.
64. Lee MK, Pardoux C, Hall MC, Lee PS, Warburton D, Qing J, Smith SM and Derynck R: TGF-β activates ERK MAP kinase signalling through direct phosphorylation of SHCA. EMBO J 26: 3957-3967, 2007.
65. Xu J, Lamouille S and Derynck R: TGF-β-induced epithelial to mesenchymal transition. Cell Res 19: 156-172, 2009.
66. Das S, Becker BN, Hoffmann FM and Mertz JE: Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the RHO pathway. BMC Cell Biol 10: 94, 2009.
67. Horiguchi K, Shirakihara T, Nakano A, Imamura T, Miyazono K and Saitoh M: Role of RAS signalling in the induction of snail by transforming growth factor-β. J Biol Chem 284: 245-253, 2009.
68. Araki S, Eitel JA, Batuello CN, Bijangi-Vishehsaraei K, Xie XJ, Danielpour D, Pollok KE, Boothman DA and Mayo LD: TGF-β1-induced expression of human MDM2 correlates with latestage metastatic breast cancer. J Clin Invest 120: 290-302, 2010.
69. Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y and Wrana JL: Regulation of the polarity protein PAR6 by TGFβ receptors controls epithelial cell plasticity. Science 307: 1603-1609, 2005.
70. Kowanetz M, Lönn P, Vanlandewijck M, Kowanetz K, Heldin CH and Moustakas A: TGFβ induces SIK to negatively regulate type I receptor kinase signalling. J Cell Biol 182: 655-662, 2008.
71. Inoue Y and Imamura T: Regulation of TGF-β family signalling by E3 ubiquitin ligases. Cancer Sci 99: 2107-2112, 2008.
72. Tang L-Y and Zhang YE: Non-degradative ubiquitination in SMAD-dependent TGF-β signalling. Cell Biosci 1: 43, 2011.
73. Bai Y, Yang C, Hu K, Elly C and Liu YC: ITCH E3 ligasemediated regulation of TGF-β signalling by modulating SMAD2 phosphorylation. Mol Cell 15: 825-831, 2004.
74. Wang D, Song H, Evans JA, Lang JC, Schuller DE and Weghorst CM: Mutation and down-regulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck. Carcinogenesis 18: 2285-2290, 1997.
75. Qiu W, Schonleben F, Li X and Su GH: Disruption of transforming growth factor β-SMAD signalling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4. Cancer Lett 245: 163-170, 2007.
76. Moren A, Hellman U, Inada Y, Imamura T, Heldin CH and Moustakas A: Differential ubiquitination defines the functional status of the tumor suppressor Smad4. J Biol Chem 278: 33571-33582, 2003.
77. Bornstein S, White R, Malkoski S, Oka M, Han G, Cleaver T, Reh D, Andersen P, Gross N, Olson S, Deng C, Lu SL and Wang XJ: Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. J Clin Invest 119: 3408-3419, 2009.
78. Schülein C, Eilers M and Popov N: PI3K-dependent phosphorylation of FBW7 modulates substrate degradation and activity. FEBS Lett 585: 2151-2157, 2011.
79. Manning BD and Cantley LC: AKT/PKB signalling: Navigating downstream. Cell 129: 1261-1274, 2007.
80. Sabatini DM: mTOR and cancer: Insights into a complex relationship. Nature Rev Cancer 6: 729-734, 2006.
81. Zheng L, Ding H, Lu Z, Li Y, Pan Y, Ning T and Ke Y: E3 ubiquitin ligase E6AP-mediated TSC2 turnover in the presence and absence of HPV16. Genes Cells 13: 285-294, 2008.
82. Oh K-J, Kalinina A, Park N-H and Bagchi S: Deregulation of eIF4E: 4E-BP1 in differentiated human papillomaviruscontaining cells leads to high levels of expression of the E7 oncoprotein. J Virol 80: 7079-7088, 2006.
83. Lo H-W, Hsu S-C, Xia W, Cao X, Shih JY, Wei Y, Abbruzzese JL, Hortobagyi GN and Hung MC: Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 67: 9066-9076, 2007.
84. Sheu JJ, Hua CH, Wan L, Lin YJ, Lai MT, Tseng HC, Jinawath N, Tsai MH, Chang NW, Lin CF, Lin CC, Hsieh LJ, Wang TL, Shihle M and Tsai FJ: Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res 69: 2568-2576, 2009.
85. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE and Salgia R: The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 69: 3021-3031, 2009.
86. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK and Ang KK: Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. New Engl J Med 354: 567-578, 2006.
87. Kupferman ME, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, Xie T, Feng L, Wang J, Holsinger FC, Yu D and Myers JN: TRKB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene 29: 2047-2059, 2010.
88. Santer FR, Moser B, Spoden GA, Jansen-Dürr P and Zwerschke W: Human papillomavirus type 16 E7 oncoprotein inhibits apoptosis mediated by nuclear insulin-like growth factor-binding protein-3 by enhancing its ubiquitin/proteasomedependent degradation. Carcinogenesis 28: 2511-2520, 2007.
89. Manenti S, Delmas C and Darbon JM: Cell adhesion protects c-Raf-1 against ubiquitin-dependent degradation by the proteasome. Biochem Biophys Res Commun 294: 976-980, 2002.
90. Lu Z, Xu S, Joazeiro C, Cobb MH and Hunter T: The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2. Mol Cell 9: 945-956, 2002.
91. Coulombe P, Rodier G, Pelletier S, Pellerin J and Meloche S: Rapid turnover of Extracellular Signal-Regulated kinase 3 by the Ubiquitin-Proteasome Pathway defines a novel paradigm of Mitogen-Activated Protein Kinase regulation during cellular differentiation. Mol Cell Biol 23: 4542-4558, 2003.
92. Guenou H, Kaabeche K, Dufour C, Miraoui H and Marie PJ: Down-regulation of ubiquitin ligase CBL induced by TWIST haploinsufficiency in Saethre-Chotzen syndrome results in increased PI3K/AKT signalling and osteoblast proliferation. Am J Pathol 169: 1303-1311, 2006.
93. Adachi M, Katsumura KR, Fujii K, Kobayashi S, Aoki H and Matsuzaki M: Proteasome-dependent decrease in Akt by growth factors in vascular smooth muscle cells. FEBS Lett 554: 77-80, 2003.
94. Soond SM, Townsend PA, Barry SP, Knight RA, Latchman DS and Stephanou A: ERK and the F-Box protein βTRCP target STAT1 for degradation. J Biol Chem 283: 16077-16083, 2008.
95. Sorkin A and von Zastrow M: Endocytosis and signalling: intertwining molecular networks. Nature Rev Mol Cell Biol 10: 609-622, 2009.
96. Joffre C, Barrow R, Ménard L, Calleja V, Hart IR and Kermorgant S: A direct role for Met endocytosis in tumorigenesis. Nature Cell Biol 13: 827-833, 2011.
97. Wang X, Trotman L, Koppie T, Alimonti A, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C, Pandolfi PP and Jiang X: NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128: 129-139, 2007.
98. Fouladkou F, Landry T, Kawabe H, Neeb A, Lu C, Brose N, Stambolic V and Rotin D: The ubiquitin ligase NEDD4-1 is dispensable for the regulation of PTEN stability and localization. Proc Natl Acad Sci USA 105: 8585-8590, 2008.
99. Baker SJ: PTEN enters the nuclear age. Cell 128: 25-28, 2007.
100. Perkins ND: The diverse and complex roles of NF-κB subunits in cancer. Nature Rev Cancer 12: 121-132, 2012.
101. Wertz IE and Dixit VM: Signaling to NF-κB: Regulation by ubiquitination. Cold Spring Harb Perspect Biol 2: a003350, 2010.
102. Voutsadakis IA: Molecular predictors of gemcitabine response in pancreatic cancer. World J Gastrointest Oncol 3: 153-164, 2011.
103. Espinosa L, Bigas A and Mulero MC: Alternative nuclear functions for NF-κB family members. Am J Cancer Res 1: 446-459, 2011.
104. Yadav A, Kumar B, Datta J, Teknos TN and Kumar P: IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signalling pathway. Mol Cancer Res 9: 1658-1667, 2011.
105. Min C, Eddy SF, Sherr DH and Sonenshein GE: NF-κB and epithelial to mesenchymal transition of cancer. J Cell Biochem 104: 733-744, 2008.
106. Kashatus D, Cogwell P and Baldwin AS: Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev 20: 225-235, 2006.
107. Schmukle AC and Walczak H: No one can whistle a symphony alone-how different ubiquitin linkages cooperate to orchestrate NF-κB activity. J Cell Sci 125: 549-559, 2012.
108. Harhaj EW and Dixit VM: Deubiquitinases in the regulation of NF-κB signalling. Cell Res 21: 22-39, 2011.
109. Cohen J, Chen Z, Lu SL, Yang XP, Arun P, Ehsanian R, Brown MS, Lu H, Yan B, Diallo O, Wang XJ and Van Waes C: Attenuated transforming growth factor β signalling promotes nuclear factor κB activation in head and neck cancer. Cancer Res 69: 3415-3424, 2009.
110. Tergaonkar V, Pando M, Vafa O, Wahl G and Verma I: p53 stabilization is decreased upon NF-κB activation: A role for NF-κB in acquisition of resistance to chemotherapy. Cancer Cell 1: 493-503, 2002.
111. Guttridge DC, Albanese C, Reuther JY, Pestell RG and Baldwin AS Jr.: NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19: 5785-5799, 1999.
112. Loercher A, Lee TL, Ricker JL, Howard A, Geoghegen J, Chen Z, Sunwoo JB, Sitcheran R, Chuang EY, Mitchell JB, Baldwin AS Jr and Van Waes C: Nuclear factor-κB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 64: 6511-6523, 2004.
113. Katayama A, Ogino T, Bandoh N, Nonaka S and Harabuchi Y: Expression of CXCR4 and its down-regulation by IFN-γ in head and neck squamous cell carcinoma. Clin Cancer Res 11: 29937-2946, 2005.
114. Taki M, Higashikawa K, Yoneda S, Ono S, Shigeishi H, Nagayama M and Kamata N: Up-regulation of stromal cellderived factor-1α and its receptor CXCR4 expression accompanied with epithelial-mesenchymal transition in human oral squamous cell carcinoma. Oncol Rep 19: 993-998, 2008.
115. Yan M, Xu Q, Zhang P, Zhou X, Zhang Z and Chen W: Correlation of NF-κB signal pathway with tumor metastasis of human head and neck squamous cell carcinoma. BMC Cancer 10: 437, 2010.
116. Mani A and Gelmann EP: The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23: 4776-4789, 2005.
117. Ruschak AM, Slassi M, Kay LE and Schimmer AD: Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst 103: 1007-1017, 2011.
118. Fostier K, De Becker A and Schots R: Carfilzomib: A novel treatment in relapsed and refractory multiple myeloma. OncoTargets Ther 5: 237-244, 2012.
119. Kisselev AF, van der Linden WA and Overkleeft HS: Proteasome inhibitors: An expanding army attacking a unique target. Chem Biol 19: 99-115, 2012.
120. Milano A, Perri F and Caponigro F: The ubiquitin-proteasome system as a molecular target in solid tumors: An update on bortezomib. Oncotargets Ther 2: 171-178, 2009.
121. Fribley A, Zeng Q and Wang CY: Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 24: 9695-9704, 2004.
122. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausvill E, Adams J, Elliott P and Van Waes C: Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 7: 1419-1428, 2001.
123. Wagenblast J, Hambek M, Baghi M, Gstöttner W, Strebhardt K, Ackermann H and Knecht R: Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 134: 323-330, 2008.
124. Weber CN, Cerniglia GJ, Maity A and Gupta AK: Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation. Cancer Biol Ther 6: 156-159, 2007.
125. Wegenblast J, Baghi M, Arnoldner C, Bisdas S, Gstöttner W, Ackermann H, May A, Hambek M and Knecht R: Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 135: 387-393, 2009
126. Lorch JH, Thomas TO and Schmoll HJ: Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. Cancer Res 67: 727-734, 2007.
127. Duan J, Friedman J, Nottingham L, Chen Z, Ara G and Van Waes C: Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 6: 37-50, 2007.
128. Li C, Li R, Grandis JR and Johnson DE: Bortezomib induces apoptosis via BIM and BIK up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Mol Cancer Ther 7: 1647-1655, 2008.
129. Kudo Y, Kitajima S, Ogawa I, Miyauchi M and Takata T: Down-regulation of CDK inhibitor p27 in oral squamous cell carcinoma. Oral Oncol 41: 105-116, 2005.
130. Kudo Y, Kitajima S, Ogawa I, Kitagawa M, Miyauchi M and Takata T: Small interfering RNA targeting of S phase kinaseinteracting protein 2 inhibits cell growth of oral cancer cells by inhibiting p27 degradation. Mol Cancer Ther 4: 471-476, 2005.
131. Chen Z, Ricker JL, Malhotra PS, Nottingham L, Bagain L, Lee TL, Yeh NT and Van Waes C: Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-κB and activator protein-1-related mechanisms. Mol Cancer Ther 7: 1949-1960, 2008.
132. Chung CH, Aulino J, Muldowney NJ, Hatakeyama H, Baumann J, Burkey B, Netterville J, Sinard R, Yarbrough WG, Cmelak AJ, Slebos RJ, Shyr Y, Parker J, Gilbert J and Murphy BA: Nuclear factor-κB pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/ or metastatic head and neck squamous cell carcinoma. Ann Oncol 21: 864-870, 2010.
133. Allen C, Saigal K, Nottingham L, Arun P, Chen Z and Van Waes C: Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-κB subunits in head and neck cancer. Clin Cancer Res 14: 4175-4185, 2008.
134. Cohen P and Tcherpakov M: Will the ubiquitin system furnish as many drug targets as protein kinases? Cell 143: 686-693, 2010.
135. Mattern MR, Wu J and Nicholson B: Ubiquitin-based anticancer therapy: Carpet bombing with proteasome inhibitors vs. surgical strikes with E1, E2, E3, or DUB inhibitors. Biochim Biophys Acta 1823: 2014-2021, 2012.
136. Allende-Vega N and Saville MK: Targeting the ubiquitin-proteasome system to activate wild-type p53 for cancer therapy. Semin Cancer Biol 20: 29-39, 2010.
137. Vassilev LT: MDM2 inhibitors for cancer therapy. Trends Mol Med 13: 23-31, 2007
138. Zhuang C, Miao Z, Zhu L, Zhang Y, Guo Z, Yao J, Dong G, Wang S, Liu Y, Chen H, Sheng C and Zhang W: Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction. Eur J Med Chem 46: 5654-5661, 2011.
139. Wang SP, Wang WL, Chang YL, Wu CT, Chao YC, Kao SH, Yuan A, Lin CW, Yang SC, Chan WK, Li KC, Hong TM and Yang PC: p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of SLUG. Nature Cell Biol 11: 694-704, 2009.
140. Yang Y, Kitagaki J, Dai RM, Tsai YC, Lorick KL, Ludwig RL, Pierre SA, Jensen JP, Davydov IV, Oberoi P, Li CC, Kenten JH, Beutler JA, Vousden KH and Weissman AM: Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res 67: 9472-9481, 2007.
141. Tsukamoto S, Hirota H, Imachi M, Fujimuro M, Onuki H, Ohta T and Yokosawa H: Himeic acid A: A new ubiquitinactivating enzyme inhibitor isolated from a marine-derived fungus, Aspergillus sp. Bioorg Med Chem Lett 15: 191-194, 2005.
142. Nakajima H, Fujiwara H, Furuichi Y, Tanaka K and Shimbara N: A novel small-molecule inhibitor of NF-κB signalling. Biochem Biophys Res Commun 368: 1007-1013, 2008.
143. Vaux DL and Silke J: IAPs, RINGs and ubiquitylation. Nature Rev Mol Cell Biol 6: 287-297, 2005.
144. Fulda S and Vucic D: Targeting IAP proteins for therapeutic intervention in cancer. Nature Rev Drug Discov 11: 109-124, 2012.
145. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT and Ogino S: Aspirin use, tumor PIK3CA mutation, and colorectal cancer survival. New Engl J Med 367: 1596-1606, 2012.
146. Voutsadakis IA, Patrikidou A, Tsapakidis K, Karagiannaki A, Hatzidaki E, Stathakis NE and Papandreou CN: Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib. Int J Colorectal Dis 25: 795-804, 2010.